Despite the impact of the COVID-19 pandemic, investment and interest in clinical trials of potential new treatments for Parkinson’s disease remains strong, according to a report. The study suggests that the landscape of developmental Parkinson’s treatments has changed little over the last year, with researchers noting a slight increase…
A new technique allowed researchers to label with specificity proteins inside neurons of the striatum — a brain region involved in voluntary movement control — within a living mouse. These findings may help scientists better understand the millions of distinct proteins in the brain and their interactions within neurons (nerve…
Worse gastrointestinal symptoms predict more severe anxiety and depression, and vice-versa, within the same year and in the following year in people with Parkinson’s disease, a study shows. This bidirectional link between gut and mental health suggests a potential cyclical relationship, in which gastrointestinal (GI) symptoms increase the risk…
More than 1 in 3 people with Parkinson’s disease (PD) are dissatisfied with their quality of life, but fully half of these patients are optimistic about what the future holds, according to results of an online survey. The survey, conducted by Parkinson’s News Today, also showed that most Parkinson’s…
A Phase 1 clinical trial in the U.K. is recruiting patients with mild to moderate Parkinson’s to assess MODAG Neuroscience Solutions‘ investigational oral therapy anle138b, which seeks to slow or halt disease progression. The trial (NCT04685265) will be conducted at a single site at Nottingham University Hospital,…
People with Parkinson’s disease who undergo deep brain stimulation (DBS) at Mount Sinai in New York, along with those scheduled for the surgical treatment, will soon have access to Q-Lab, a newly opening immersive and interactive rehabilitation and research facility. A collaboration between the Nash Family Center…
People with Parkinson’s disease who use medications for epilepsy reported a poorer quality of life on questionnaires than did those who do not, a study reported. Quality of life (QoL) was also lower in those who used a higher number of medicines to treat the disease’s non-motor symptoms. “Physicians should…
Eight grants worth a total of $575,000 were awarded by the McCamish Parkinson’s Disease Innovation Program to research teams at Georgia Tech and Emory University advancing projects into Parkinson’s disease. “These grants are specifically focused on technology-driven research for understanding, treating, and curing Parkinson’s disease,” Garrett Stanley, PhD, professor…
Patient dosing has been completed in the Phase 2a clinical trial testing ANVS401, Annovis Bio’s investigational therapy for Alzheimer’s disease and Parkinson’s disease. An additional 40 patients with Parkinson’s disease were treated with ANVS401, with the company now preparing to share final safety and efficacy data later this year. According to…
Three months of Xadago (safinamide) as an add-on therapy lessened symptoms of rapid eye movement sleep behavior disorder (RBD) in people with Parkinson’s disease, a pilot study in patients reported. The study, “Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal,…
Get regular updates to your inbox.